Evaluation of the Application Efect of PaRftZLfx Regimen in Refractory Pulmonary Tuberculosis/ HUANG Ziqiang， ZHU Jing， ZHANG She， WU Junjie. //Medical Innovation of China， 2025， 22(11)： 144-148

    [Abstract]Objective： To explore the value of PaRfZLfx regimen in the treatment of refractory pulmonary tuberculosis.Method：Atotal of 80patients withrefractorypulmonarytuberculosiswereselected， allof whom were admitted to the Department of Lung Disease of Yangzhou Third People's Hospital from February 2022 to October 2023.They were randomly divided into two groups according to the random number method.The control group (40 cases) received LfxEPAS chemotherapy regimen， while the observation group (40 cases)received PaRfZLfx treatment.The clinical eficacy after3 months of treatment，sputumconversionrate after 2， 4，and 6 monthsof treatment，cavityclosure after 6 months oftreatment， incidence ofadverse reactionswithin 3 months，and changes in immune functionafter 3 monthsof treatment were compared.Result：The totaleffctiverate，sputum conversion rate，andcavityclosure intheobservation groupwere allbeterthanthose inthecontrol group ......